Literature DB >> 2987571

[Agents to improve cerebrovascular circulation and cerebral metabolism--vinpocetine].

N Tamaki, S Matsumoto.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2987571

Source DB:  PubMed          Journal:  Nihon Rinsho        ISSN: 0047-1852


× No keyword cloud information.
  8 in total

1.  Vinpocetine inhibits Streptococcus pneumoniae-induced upregulation of mucin MUC5AC expression via induction of MKP-1 phosphatase in the pathogenesis of otitis media.

Authors:  Ji-Yun Lee; Kensei Komatsu; Byung-Cheol Lee; Masanori Miyata; Ashley O'Neill Bohn; Haidong Xu; Chen Yan; Jian-Dong Li
Journal:  J Immunol       Date:  2015-05-13       Impact factor: 5.422

2.  Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism.

Authors:  Kye-Im Jeon; Xiangbin Xu; Toru Aizawa; Jae Hyang Lim; Hirofumi Jono; Dong-Seok Kwon; Jun-Ichi Abe; Bradford C Berk; Jian-Dong Li; Chen Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-06       Impact factor: 11.205

3.  Vinpocetine inhibits amyloid-beta induced activation of NF-κB, NLRP3 inflammasome and cytokine production in retinal pigment epithelial cells.

Authors:  Ruozhou Tom Liu; Aikun Wang; Eleanor To; Jiangyuan Gao; Sijia Cao; Jing Z Cui; Joanne A Matsubara
Journal:  Exp Eye Res       Date:  2014-07-17       Impact factor: 3.467

4.  Vinpocetine attenuates lipid accumulation and atherosclerosis formation.

Authors:  Yujun Cai; Jian-Dong Li; Chen Yan
Journal:  Biochem Biophys Res Commun       Date:  2013-04-10       Impact factor: 3.575

5.  Vinpocetine suppresses pathological vascular remodeling by inhibiting vascular smooth muscle cell proliferation and migration.

Authors:  Yujun Cai; Walter E Knight; Shujie Guo; Jian-Dong Li; Peter A Knight; Chen Yan
Journal:  J Pharmacol Exp Ther       Date:  2012-08-22       Impact factor: 4.030

6.  Efficacy and Safety of Vinpocetine as Part of Treatment for Acute Cerebral Infarction: A Randomized, Open-Label, Controlled, Multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) Trial.

Authors:  Weiwei Zhang; Yining Huang; Ying Li; Liming Tan; Jianfei Nao; Hongtao Hu; Jingyu Zhang; Chen Li; Yuenan Kong; Yulin Song
Journal:  Clin Drug Investig       Date:  2016-09       Impact factor: 2.859

7.  The Relieving Effects of BrainPower Advanced, a Dietary Supplement, in Older Adults with Subjective Memory Complaints: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Jingfen Zhu; Rong Shi; Su Chen; Lihua Dai; Tian Shen; Yi Feng; Pingping Gu; Mina Shariff; Tuong Nguyen; Yeats Ye; Jianyu Rao; Guoqiang Xing
Journal:  Evid Based Complement Alternat Med       Date:  2016-04-11       Impact factor: 2.629

8.  Vinpocetine alleviate cerebral ischemia/reperfusion injury by down-regulating TLR4/MyD88/NF-κB signaling.

Authors:  Li-Rong Wu; Liang Liu; Xiao-Yi Xiong; Qin Zhang; Fa-Xiang Wang; Chang-Xiong Gong; Qi Zhong; Yuan-Rui Yang; Zhao-You Meng; Qing-Wu Yang
Journal:  Oncotarget       Date:  2017-09-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.